Emerald Advisers LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 8,845 shares of the biotechnology company’s stock, valued at approximately $915,000. Other hedge funds and other institutional investors have also recently bought […]
DekaBank Deutsche Girozentrale boosted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 2.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 296,567 shares of the biotechnology company’s stock after buying an additional 7,280 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in BioMarin Pharmaceutical were worth $30,273,000 as of its […]
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) has received a consensus rating of “Hold” from the twenty-three research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating on the company. […]
Rice Hall James & Associates LLC grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 63.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,408 shares of the biotechnology company’s stock after purchasing an additional […]
Manning & Napier Group LLC decreased its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 6.1% during the fourth quarter, HoldingsChannel reports. The firm owned 874,566 shares of the biotechnology company’s stock after selling 57,225 shares during the period. BioMarin Pharmaceutical makes up approximately 1.1% of Manning & Napier Group LLC’s […]